A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma

Winnie Yeo, T. W.T. Leung, Anthony Tak-cheung Chan, S. K.W. Chiu, P. Yu, Tony Shu-kam Mok, P. J. Johnson

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

The aim of this study was to determine the efficacy and toxicity of combination paclitaxel and carboplatin chemotherapy in patients with metastatic and/or locoregionally advanced nasopharyngeal carcinoma (NPC). Patients with metastatic and/or locoregionally advanced NPC were treated with carboplatin calculated according to an AUC of 6mgml/min (based on Calvert formula) given as an intravenous (i.v.) bolus, followed by paclitaxel 135 mg/ml2 given as an i.v. infusion over 3 h with standard premedication. Cycles were given 3 weekly to a maximum of six. From January 1996 to November 1997, 27 patients were entered and assessable for response and toxicity. A total of 122 cycles were given and the median number of cycles given was five. The overall response rate was 59% (16/27). There were 3 (11%) complete responses, 13 (48%) partial responses, 5 (19%) static disease and 6 (22%) progressive disease. Toxicity was mainly haematological including: grade 3/4 neutropenia (39 cycles, 32%), grade 3/4 anaemia (nine cycles, 7%), grade 3/4 thrombocytopenia (eight cycles, 7%). There were three episodes of neutropenic fever (3%). Non-haematological toxicities were mild and infrequent. Paclitaxel and carboplatin combination chemotherapy is active in NPC and has tolerable toxicity. Further study with dose escalation is required to assess its optimal efficacy.

Original languageEnglish (US)
Pages (from-to)2027-2031
Number of pages5
JournalEuropean Journal of Cancer
Volume34
Issue number13
DOIs
StatePublished - Dec 1 1998

Fingerprint

Carboplatin
Paclitaxel
Premedication
Combination Drug Therapy
Neutropenia
Intravenous Infusions
Area Under Curve
Anemia
Fever
Drug Therapy
Nasopharyngeal carcinoma

Keywords

  • Carboplatin
  • Metastatic/recurrent nasopharyngeal carcinoma
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yeo, W., Leung, T. W. T., Chan, A. T., Chiu, S. K. W., Yu, P., Mok, T. S., & Johnson, P. J. (1998). A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. European Journal of Cancer, 34(13), 2027-2031. https://doi.org/10.1016/S0959-8049(98)00280-9

A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. / Yeo, Winnie; Leung, T. W.T.; Chan, Anthony Tak-cheung; Chiu, S. K.W.; Yu, P.; Mok, Tony Shu-kam; Johnson, P. J.

In: European Journal of Cancer, Vol. 34, No. 13, 01.12.1998, p. 2027-2031.

Research output: Contribution to journalArticle

Yeo, W, Leung, TWT, Chan, AT, Chiu, SKW, Yu, P, Mok, TS & Johnson, PJ 1998, 'A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma', European Journal of Cancer, vol. 34, no. 13, pp. 2027-2031. https://doi.org/10.1016/S0959-8049(98)00280-9
Yeo, Winnie ; Leung, T. W.T. ; Chan, Anthony Tak-cheung ; Chiu, S. K.W. ; Yu, P. ; Mok, Tony Shu-kam ; Johnson, P. J. / A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. In: European Journal of Cancer. 1998 ; Vol. 34, No. 13. pp. 2027-2031.
@article{970a9e3e93174091a96beba14f6b5492,
title = "A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma",
abstract = "The aim of this study was to determine the efficacy and toxicity of combination paclitaxel and carboplatin chemotherapy in patients with metastatic and/or locoregionally advanced nasopharyngeal carcinoma (NPC). Patients with metastatic and/or locoregionally advanced NPC were treated with carboplatin calculated according to an AUC of 6mgml/min (based on Calvert formula) given as an intravenous (i.v.) bolus, followed by paclitaxel 135 mg/ml2 given as an i.v. infusion over 3 h with standard premedication. Cycles were given 3 weekly to a maximum of six. From January 1996 to November 1997, 27 patients were entered and assessable for response and toxicity. A total of 122 cycles were given and the median number of cycles given was five. The overall response rate was 59{\%} (16/27). There were 3 (11{\%}) complete responses, 13 (48{\%}) partial responses, 5 (19{\%}) static disease and 6 (22{\%}) progressive disease. Toxicity was mainly haematological including: grade 3/4 neutropenia (39 cycles, 32{\%}), grade 3/4 anaemia (nine cycles, 7{\%}), grade 3/4 thrombocytopenia (eight cycles, 7{\%}). There were three episodes of neutropenic fever (3{\%}). Non-haematological toxicities were mild and infrequent. Paclitaxel and carboplatin combination chemotherapy is active in NPC and has tolerable toxicity. Further study with dose escalation is required to assess its optimal efficacy.",
keywords = "Carboplatin, Metastatic/recurrent nasopharyngeal carcinoma, Paclitaxel",
author = "Winnie Yeo and Leung, {T. W.T.} and Chan, {Anthony Tak-cheung} and Chiu, {S. K.W.} and P. Yu and Mok, {Tony Shu-kam} and Johnson, {P. J.}",
year = "1998",
month = "12",
day = "1",
doi = "10.1016/S0959-8049(98)00280-9",
language = "English (US)",
volume = "34",
pages = "2027--2031",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "13",

}

TY - JOUR

T1 - A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma

AU - Yeo, Winnie

AU - Leung, T. W.T.

AU - Chan, Anthony Tak-cheung

AU - Chiu, S. K.W.

AU - Yu, P.

AU - Mok, Tony Shu-kam

AU - Johnson, P. J.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - The aim of this study was to determine the efficacy and toxicity of combination paclitaxel and carboplatin chemotherapy in patients with metastatic and/or locoregionally advanced nasopharyngeal carcinoma (NPC). Patients with metastatic and/or locoregionally advanced NPC were treated with carboplatin calculated according to an AUC of 6mgml/min (based on Calvert formula) given as an intravenous (i.v.) bolus, followed by paclitaxel 135 mg/ml2 given as an i.v. infusion over 3 h with standard premedication. Cycles were given 3 weekly to a maximum of six. From January 1996 to November 1997, 27 patients were entered and assessable for response and toxicity. A total of 122 cycles were given and the median number of cycles given was five. The overall response rate was 59% (16/27). There were 3 (11%) complete responses, 13 (48%) partial responses, 5 (19%) static disease and 6 (22%) progressive disease. Toxicity was mainly haematological including: grade 3/4 neutropenia (39 cycles, 32%), grade 3/4 anaemia (nine cycles, 7%), grade 3/4 thrombocytopenia (eight cycles, 7%). There were three episodes of neutropenic fever (3%). Non-haematological toxicities were mild and infrequent. Paclitaxel and carboplatin combination chemotherapy is active in NPC and has tolerable toxicity. Further study with dose escalation is required to assess its optimal efficacy.

AB - The aim of this study was to determine the efficacy and toxicity of combination paclitaxel and carboplatin chemotherapy in patients with metastatic and/or locoregionally advanced nasopharyngeal carcinoma (NPC). Patients with metastatic and/or locoregionally advanced NPC were treated with carboplatin calculated according to an AUC of 6mgml/min (based on Calvert formula) given as an intravenous (i.v.) bolus, followed by paclitaxel 135 mg/ml2 given as an i.v. infusion over 3 h with standard premedication. Cycles were given 3 weekly to a maximum of six. From January 1996 to November 1997, 27 patients were entered and assessable for response and toxicity. A total of 122 cycles were given and the median number of cycles given was five. The overall response rate was 59% (16/27). There were 3 (11%) complete responses, 13 (48%) partial responses, 5 (19%) static disease and 6 (22%) progressive disease. Toxicity was mainly haematological including: grade 3/4 neutropenia (39 cycles, 32%), grade 3/4 anaemia (nine cycles, 7%), grade 3/4 thrombocytopenia (eight cycles, 7%). There were three episodes of neutropenic fever (3%). Non-haematological toxicities were mild and infrequent. Paclitaxel and carboplatin combination chemotherapy is active in NPC and has tolerable toxicity. Further study with dose escalation is required to assess its optimal efficacy.

KW - Carboplatin

KW - Metastatic/recurrent nasopharyngeal carcinoma

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0032402238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032402238&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(98)00280-9

DO - 10.1016/S0959-8049(98)00280-9

M3 - Article

C2 - 10070305

AN - SCOPUS:0032402238

VL - 34

SP - 2027

EP - 2031

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 13

ER -